Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tagitanlimab |
| Synonyms | |
| Therapy Description |
Tagitanlimab (KL-A167) is a monoclonal antibody targeting CD274 (PD-L1), which potentially inhibits tumor growth (PMID: 40830660, PMID: 36879786). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tagitanlimab | KLA167|KL-A167|KL A167 | PD-L1/PD-1 antibody 134 | Tagitanlimab (KL-A167) is a monoclonal antibody targeting CD274 (PD-L1), which potentially inhibits tumor growth (PMID: 40830660, PMID: 36879786). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|